Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp173 | Cell biology: osteoclasts and bone resorption | ECTS2014

Inhibition of bone remodeling by bisphosphonate displaces the plasma cell niche into the spleen

Teufel Stefan , Grotsch Bettina , Luther Julia , Schinke Thorsten , Amling Michael , Schett Georg , Mielenz Dirk , David Jean-Pierre

Bone marrow is the main hematopoietic organ of adults. There, hematopoietic stem cells from which all hematopoietic lineages can be generated are preferentially homing. Importantly, bone provides niches for early B cell differentiation and survival of long-lived plasma cells that produced antibodies. Thus, that perturbing bone homeostasis might impact B cell function and antibody production is a highly relevant hypothesis for patients receiving antiresorptive drugs.<p clas...

ba0003pp355 | Osteoporosis: treatment | ECTS2014

Continuous modelling-based bone formation could explain sustained increases in hip bone mineral density with denosumab treatment

Ominsky Michael S , Libanati Cesar , Boyce Rogely , Kostenuik Paul J , Baron Roland , Wagman Rachel B , Dempster David W

In clinical studies, denosumab (DMAb) administration up to 8 years is associated with continued increases in bone mineral density (BMD) and low fracture incidence despite persistently low bone turnover markers and limited iliac crest tetracycline labelling (Papapoulos 2013). We tested the hypothesis that, with persistently low bone remodelling, BMD increases may result from a non-remodelling dependent mechanism to accrue bone matrix. We examined the fluorochrome labelling patt...

ba0004p201 | (1) | ICCBH2015

The results of pamidronate treatment independently and in combination with surgery in patients with osteogenesis imperfecta.

Zyma Andrii , Guk Iurii , Gayko Oksana , Magomedov Oleksandr , Kinchaya-Polishchuk Tamara , Stewart David , Cheverda Andriy , Demyan Yuriy

Introduction: The effectiveness of intravenous pamidronate was assessed independently and in combination with corrective osteotomy surgery for lower extremity deformities in children with osteogenesis imperfecta.Methods: Orthopaedic treatment was conducted in 21 patients with OI (type I–ten patients, type III–11 patients), including 13 males and eight females with mean age 9.4±0.6. All patients received calcium supplements and active forms...

ba0005p102 | Cancer and bone: basic, translational and clinical | ECTS2016

Inhibition of mTOR signaling by everolimus has concurrent anti-tumor and bone-protective effects in murine osteolytic cancer models

Browne Andrew , Kubasch Marie Luise , Gobel Andy , Hadji Peyman , Chen David , Rauner Martina , Rachner Tilman , Hofbauer Lorenz

Clinical data suggest that the mTOR inhibitor everolimus may have bone protective effects in addition to its anti-tumor effects in women with ER+/HER2− metastatic breast cancer receiving hormone-ablative therapies. Based on these findings, we tested the hypothesis, whether everolimus exerts concurrent anti-tumor effects while protecting the skeleton in murine models. Thus, we assessed bone metabolism and anti-tumor effects in osteolytic cancer models upon exposure to eve...

ba0005p317 | Osteoporosis: evaluation and imaging | ECTS2016

Cellular and extracellular investigations of healing parameters in a sheep model of osteoporosis

Schaefer Annemarie , Rosch Sebastian , Weisweiler David , Boecker Wolfgang , Lips Katrin S , Heiss Christian , Malhan Deeksha , Khassawna Thaqif El

Due to its huge socio-economic impact a better understating of osteoporotic fracture healing is crucial.Thirty-one female merino land sheep were randomly divided into four groups. (i) Untreated control-group (C, n=8); (ii) bilateral ovariectomy (OVX, n=7); (iii) OVX and calcium-deficient diet (OVXD, n=8); and (iv) OVXD and additional biweekly corticosteroid injections (OVXDS, n=8). Drill-hole defects (7.5 mm in diamete...

ba0006p029 | (1) | ICCBH2017

Web-based surveys using Patient-Reported Outcome Measurement Information System (PROMIS) instruments allow documentation of important components of the disease experience among individuals with Osteogenesis Imperfecta

Tosi Laura , Floor Marianne , Holland Rosalie , Goerlich Cara , Hart Tracy , Cuthbertson David , Sutton V Reid , Krischer Jeffrey

Objectives: Two important goals of the Rare Diseases Clinical Research Network Brittle Bone Disorders Consortium (RDCRN BBD) are i) to perform collaborative clinical research in brittle bone disorders including a longitudinal observational study driven by genotypic association and ii) to explore use of the PROMIS tool to provide valid quality of life (QOL) measures in individuals with Osteogenesis Imperfecta (OI). This work has been motivated by the fact that all current outco...

ba0007p162 | (1) | ICCBH2019

Bone monitoring and morbidity in adults with duchenne muscular dystrophy: Challenges in implementation of standards of care

Harris Anne-Marie , Di Marco Marina , Raeside David , Davidson Scott , Gallacher Stephen , Farrugia Maria , Wong Sze Choong

Background: Osteoporosis is common in subjects with Duchenne muscular dystrophy (DMD). Studies in paediatric DMD identified a high frequency of fragility fractures but there are no studies in the adult population. Recent updated international standards of care (2018) for children and adults with DMD recommend the following for bone monitoring:- Lateral thoracolumbar spine x-rays to screen for vertebral fracture (1–2 yearly if on glucocorticoid; 2&#1...

ba0001oc5.4 | Treatment of osteoporosis | ECTS2013

Effects of romosozumab administration on trabecular and cortical bone assessed with quantitative computed tomography and finite element analysis

Graeff C , Campbell G , Pena J , Padhi D , Grossman A , Chang S , Libanati C , Gluer C-C

Romosozumab is an investigational bone-forming agent that inhibits sclerostin. Recent data demonstrated that it stimulated bone formation, decreased bone resorption, and led to rapid and substantial increases in areal bone mineral density (BMD; McClung, J Bone Miner Res 27 (S1) S8–S9, 2012). In a Phase 1b, randomized, double-blind, placebo-controlled, multiple dose study, we studied the effects of romosozumab administered for 3 months and follow-...

ba0001pp249 | Chondrocytes and cartilage | ECTS2013

Impairment of endochondral ossification by Hoxa2 overexpression: a plausible molecular explanation of idiopathic proportionate short stature

Deprez Pierre M L , Nichane Miloud G , Lengele Benoit , Rezsohazy Rene , Nyssen-Behets Catherine

Introduction: Using transgenic mice ectopically expressing Hoxa2 all along chondrogenesis, we previously associated the resulting animal phenotype to human idiopathic proportionate short stature. Our analysis showed that this overall size reduction was due to a negative influence of Hoxa2 in the very first step of endochondral ossification. As the molecular pathways underlying this pathogenesis are still unknown, we here tried to identify the impact of Hoxa2 overexpression on ...